Next Article in Journal
The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity
Next Article in Special Issue
Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer’s Disease and Prediction of Cognitive Decline
Previous Article in Journal
Dual-energy X-ray Absorptiometry of Both Hips Helps Appropriate Diagnosis of Low Bone Mineral Density and Osteoporosis
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Diagnostics 2017, 7(3), 42;

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside

Department of Neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, Münster 48149, Germany
Authors to whom correspondence should be addressed.
Received: 6 May 2017 / Revised: 21 June 2017 / Accepted: 6 July 2017 / Published: 13 July 2017
(This article belongs to the Special Issue Alzheimer's Disease Imaging Biomarkers)
Full-Text   |   PDF [837 KB, uploaded 13 July 2017]   |  


Alzheimer’s disease is the most common cause of dementia. Over the last three decades, research has advanced dramatically and provided a detailed understanding of the molecular events underlying the pathogenesis of Alzheimer’s disease. In parallel, assays for the detection of biomarkers that reflect the typical Alzheimer’s disease-associated pathology have been developed and validated in myriads of clinical studies. Such biomarkers complement clinical diagnosis and improve diagnostic accuracy. The use of biomarkers will become even more important with the advent of disease-modifying therapies. Such therapies will likely be most beneficial when administered early in the disease course. Here, we summarise the development of the core Alzheimer’s disease cerebrospinal fluid biomarkers: amyloid-β and tau. We provide an overview of their role in cellular physiology and Alzheimer’s disease pathology, and embed their development as cerebrospinal fluid biomarkers into the historical context of Alzheimer’s disease research. Finally, we summarise recommendations for their use in clinical practice, and outline perspectives for novel cerebrospinal fluid candidate biomarkers. View Full-Text
Keywords: Alzheimer’s disease; dementia; fluid biomarkers; cerebrospinal fluid; amyloid-β; tau Alzheimer’s disease; dementia; fluid biomarkers; cerebrospinal fluid; amyloid-β; tau

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pawlowski, M.; Meuth, S.G.; Duning, T. Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside. Diagnostics 2017, 7, 42.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top